Navigation Links
Patent Problems in US – Over Stem Cell Researc

Alongside the setbacks the Novartis seems to be receiving in its efforts to patent its anti-cancer drug Glivec, comes the news that the US Patent// and Trademark Office has made a preliminary decision to revoke three fundamental patents on human embryonic stem cells granted in the last few years.

Patent examiners rejected all the claims of the three patents based on the works of James A.Thomson of the University of Wisconsin, perhaps the first to isolate human embryonic stem cells and grow them in culture.

Thomson’s cells appeared to be the same as, or obvious variations of, cells described in earlier scientific papers or in patents issued to others.

The Wisconsin Alumni Research Foundation (WARF) shocked but up a brave front saying finally they would win back the patents.

Invoking almost the same arguments used by anti-Novartis activists, the Public Patent Foundation said it believed patents issued earlier to Thomson’s cells were not in public interest.

A Californian consumer group said the patents impeded that state’s three billion US dollar stem cell research programme.

Actually Thomson’s isolation of stem cells nine years ago did set off a big effort to turn that basic technology into treatments for various diseases. But then the Wisconsin patents were too broad and their enforcement stymied research, critics say.

Now that the patents have been revoked, things could change, they hope.

However the matter is far from over and the WARF would go all out to defend its turf, it is expected.
GP/M
'"/>




Page: 1

Related medicine news :

1. Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations
2. HIV Patients Opposes Patenting Of AIDS Drug
3. Provigil Patent Extension Accorded To Cephalon
4. AIDS Sufferers Protest against Proposed Patent for Tenofovir
5. POLY Medicure Ltd Applies for 8 Patents, 2 FDA Approvals
6. Venus Remedies Files 5th International Patent Application
7. US Court Rules Against Lupin in Ramipril Patent Case
8. Patent for Seminal RNAi innovation Cleared in Australia
9. Canada: On Popular Demand, Tamiflu finds a Berth in the Directory of Patent Drugs
10. Compellis Pharmaceuticals Gets Patent for Obesity-Fighting Nasal Spray CP404
11. A Patented Device for Rapid Diagnosis of Diseases
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... 2017 , ... Driving Dynamics Inc., announced today it has been selected as ... part of its mission to continually monitor the training marketplace for the best providers ... 20 Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard ... businesses and organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released ... own QMS, with a deadline of September 2018. , As described in ...
(Date:9/19/2017)... ... September 19, 2017 , ... Bone ... launch of its magnesium-based orthopedic medical device, OsteoCrete®. OsteoCrete® bone void filler is ... the U.S. to incorporate magnesium, a critical property for bone health and development. ...
(Date:9/19/2017)... ... , ... First Choice Emergency Room , the largest network of independent ... Medical Director of its Pflugerville- FM 685 facility. , “We are pleased to ... 685 location,” said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... the country with the Davidson Fellows Scholarship on September 27 at a reception ... in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored to ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017   PDI , a leader in ... host an educational session focused on the role of ... prevention at the 2017 Annual Scientific Meeting of the ... place at the Phoenix Convention ... Sept. 16-19, will also feature PDI,s Prevantics® Device ...
(Date:9/6/2017)... 2017 Eli Lilly and Company (NYSE: ... data for galcanezumab and lasmiditan, two investigational treatments for ... Society (IHC) taking place Sept. 7-10 in ... new, long-term data from an open-label study evaluating the ... mg and 240 mg) for the prevention of migraine. ...
(Date:9/5/2017)... NEWTOWN, Pa. , Sept. 5, 2017  Xyntek Inc. has announced another ... opened a new Midwest office to meet the growing demands of customer engagements ... Xyntek's new Midwest office is located at ... ... demands of customer engagements regionally. ...
Breaking Medicine Technology: